Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide
Clinical trial evaluates the prognostic impact of induction responses for improvement in progression-free survival in mantle cell lymphoma patients receiving chemoimmunotherapy.
Key Points
Interim PET-positive mantle cell lymphoma patients had median progression-free survival of 4.9 years, versus 7.4 years for negative.
Patients with complete remission and negative end-of-induction bone marrow biopsy had median overall survival of 10.1 years.
Analysis included patients receiving front-line chemoimmunotherapy, assessing predictive value of PET/CT and bone marrow biopsy.
Findings suggest that end-of-induction bone marrow biopsy may not be necessary for patients who achieve metabolic complete remission.